BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30380599)

  • 1. Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
    Rustum YM; Chintala S; Durrani FA; Bhattacharya A
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy.
    Rustum YM; Reis R; Rustum TM
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell carcinoma via microRNA-21/ HIF-1α axis signals.
    Wu TK; Wei CW; Pan YR; Hsu RJ; Wu CY; Yu YL
    Sci Rep; 2019 Mar; 9(1):3207. PubMed ID: 30824757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
    Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
    Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high
    Miikkulainen P; Högel H; Seyednasrollah F; Rantanen K; Elo LL; Jaakkola PM
    J Biol Chem; 2019 Mar; 294(10):3760-3771. PubMed ID: 30617181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
    Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
    Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting renal cell carcinoma with a HIF-2 antagonist.
    Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
    Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways.
    Selvarajah J; Nathawat K; Moumen A; Ashcroft M; Carroll VA
    Cell Death Dis; 2013 Oct; 4(10):e865. PubMed ID: 24136229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.
    Martínez-Sáez O; Gajate Borau P; Alonso-Gordoa T; Molina-Cerrillo J; Grande E
    Crit Rev Oncol Hematol; 2017 Mar; 111():117-123. PubMed ID: 28259286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gramicidin A blocks tumor growth and angiogenesis through inhibition of hypoxia-inducible factor in renal cell carcinoma.
    David JM; Owens TA; Inge LJ; Bremner RM; Rajasekaran AK
    Mol Cancer Ther; 2014 Apr; 13(4):788-99. PubMed ID: 24493697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma.
    Liu Y; Tan X; Liu W; Chen X; Hou X; Shen D; Ding Y; Yin J; Wang L; Zhang H; Yu Y; Hou J; Thompson TC; Cao G
    Chin J Cancer; 2018 Jan; 37(1):2. PubMed ID: 29357946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
    Carroll VA; Ashcroft M
    Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Various forms of HIF-1α protein characterize the clear cell renal cell carcinoma cell lines.
    Swiatek M; Jancewicz I; Kluebsoongnoen J; Zub R; Maassen A; Kubala S; Udomkit A; Siedlecki JA; Sarnowski TJ; Sarnowska E
    IUBMB Life; 2020 Jun; 72(6):1220-1232. PubMed ID: 32250548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
    Wang X; Solban N; Khanna P; Callea M; Song J; Alsop DC; Pearsall RS; Atkins MB; Mier JW; Signoretti S; Alimzhanov M; Kumar R; Bhasin MK; Bhatt RS
    Oncotarget; 2016 Jul; 7(27):41857-41869. PubMed ID: 27248821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma.
    Yu Y; Yu Q; Zhang X
    Drug Discov Today; 2019 Dec; 24(12):2332-2340. PubMed ID: 31541711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.
    Xu J; Wang B; Xu Y; Sun L; Tian W; Shukla D; Barod R; Grillari J; Grillari-Voglauer R; Maxwell PH; Esteban MA
    Oncogene; 2012 Feb; 31(8):1065-72. PubMed ID: 21841824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
    Shinojima T; Oya M; Takayanagi A; Mizuno R; Shimizu N; Murai M
    Carcinogenesis; 2007 Mar; 28(3):529-36. PubMed ID: 16920734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.